| Abstrakt: |
Researchers at University Hospital Basel in Switzerland have published a new report on hematopoietic stem cells, specifically focusing on the JAK2-V617F mutation that causes myeloproliferative neoplasm (MPN). The study found that interleukin-13 (IL-13) inflammation may promote the progression of JAK2-V617F CHIP (clonal hematopoiesis of indeterminate potential) to MPN. The loss of IL-1 beta in JAK2-mutant hematopoietic stem cells (HSCs) reduced engraftment, restricted clonal expansion, and decreased the rate of conversion to MPN. These findings suggest that IL-1 beta could be a potential therapeutic target for preventing the transition from CHIP to MPNs. [Extracted from the article] |
